SCHEMBL5222434

SCHEMBL5222434

CC(C)(N)Cc1cccc(Cl)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 2/20 0.59
HTR2A P28223 1/20 0.59
SLC6A4 P31645 1/20 0.59
HRH1 P35367 1/20 0.59
HTR2B P41595 1/20 0.59
CHRNA4 P43681 1/20 0.59
SLC6A3 Q01959 1/20 0.59
TAAR1 Q96RJ0 4/20 0.57
PNMT P11086 2/20 0.55
IDO1 P14902 3/20 0.50
CYP3A4 P08684 2/20 0.50
AGXT P21549 2/20 0.50
AOC3 Q16853 1/20 0.49
HTR3E A5X5Y0 3/20 0.47
HTR3B O95264 3/20 0.47
HTR3A P46098 3/20 0.47
HTR3D Q70Z44 3/20 0.47
HTR3C Q8WXA8 3/20 0.47
ALDH1A1 P00352 1/20 0.45
GLA P06280 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL73643 0.83 PNMT (0.54) TAAR1PNMTIDO1CYP3A4AGXT
Ammonia Solution, Strong SCHEMBL27962080 0.82 PNMT (0.52) TAAR1PNMTIDO1CYP3A4AGXT
SCHEMBL27962079 0.81 PNMT (0.57) TAAR1PNMTIDO1CYP3A4AGXT
SCHEMBL8867384 0.80 KIF11 (0.48) SLC6A2TAAR1PNMTIDO1CYP3A4
SCHEMBL8324906 0.80 MAOB (0.52) TAAR1PNMTIDO1CYP3A4AGXT
SCHEMBL7109269 0.80 PNMT (0.50) TAAR1PNMTIDO1CYP3A4AGXT
SCHEMBL6617434 0.79 SLC6A2 (0.61) SLC6A2HTR2ASLC6A4HRH1HTR2B
SCHEMBL4340077 0.79 BLM (0.58) TAAR1PNMTCYP3A4HTR3EHTR3B
SCHEMBL6340256 0.79 BLM (0.58) TAAR1PNMTCYP3A4HTR3EHTR3B
SCHEMBL27699328 0.79 BLM (0.58) TAAR1PNMTCYP3A4HTR3EHTR3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7253198-B2 Hydroxyethylamine derivatives for the treatment of Alzheimer's disease GLAXO GROUP LIMITED (GB) 2007-08-07 US disclosed
EP-1567488-B1 HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE GLAXO GROUP LTD (GB) 2007-02-21 EP disclosed
CN-1735592-A Hydroxyethylamine derivatives for the treatment of alzheimer's disease GLAXO GROUP LTD (GB) 2006-02-15 CN disclosed
US-20060025459-A1 Hydroxyethylamine derivatives for the treatment of alzheimer's disease GLAXO GROUP LIMITED (GB) 2006-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060025459-A1 Hydroxyethylamine derivatives for the treatment of alzheimer's disease BACE2, PSEN2, BACE1 SLC6A2 78/4885HTR2A 48/4885SLC6A4 472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.